Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 | The Motley Fool
This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.

Source: The Motley Fool
This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.